1 / 2

Blincyto 38.5 mcg injection for ALL | 9310090915

Blincyto (blinatumomab) is a medication used to treat a type of blood cancer called B-cell precursor acute lymphoblastic leukemia (ALL). It is given as an intravenous infusion or injection.<br><br>Blincyto works by attaching to two different proteins on the surface of cancerous and normal B-cells, and then bringing these cells together, which triggers an immune response against the cancer cells. This helps to destroy the cancer cells and prevent them from spreading.<br><br>The dosing and administration of Blincyto depends on several factors, including the patient's body weight, the severity of their condi

import
Download Presentation

Blincyto 38.5 mcg injection for ALL | 9310090915

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Blincyto 38.5 mcg injection for acute lymphoblastic leukemia (ALL). Blincyto (blinatumomab) is a medication used to treat a specific type of blood cancer called Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The dose of Blincyto is based on the patient's weight and is given as a continuous intravenous infusion. The recommended starting dose for adults is 9 mcg/day, which is gradually increased over several days to a target dose of 28 mcg/day. The maximum dose is 42 mcg/day. However, you mentioned "38.5 mcg," which is not a standard dosage for Blincyto. It's possible that you made a mistake in your question or that you have been prescribed a different dosage based on your individual circumstances. In any case, it's important to follow your healthcare provider's instructions regarding the dose and administration of Blincyto or any other medication. BLINCYTO TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA Blinatumomab (brand name Blincyto) is a medication used to treat a specific type of acute lymphoblastic leukemia (ALL) called Philadelphia chromosome-negative B-cell precursor ALL. Blinatumomab is a type of immunotherapy called a bispecific T-cell engager (BiTE) that works by connecting T-cells to cancer cells, which can help the immune system identify and destroy the cancer cells. Blinatumomab is given as an intravenous infusion over a period of four weeks, followed by a two- week break, and then another four-week infusion cycle. Treatment typically lasts for a total of six cycles. The medication is given in a hospital or infusion center, and patients are closely monitored for potential side effects. Common side effects of Blinatumomab include fever, fatigue, headache, nausea, vomiting, diarrhea, and decreased appetite. More serious side effects can include infections, allergic reactions, neurological problems, and cytokine release syndrome, which is a potentially life-threatening

  2. immune response. Patients receiving Blinatumomab may also experience low levels of certain blood cells, which can increase the risk of bleeding or infections. Blinatumomab can be a highly effective treatment for certain types of ALL, but it is not suitable for everyone. It is important to discuss the potential risks and benefits of this medication with your doctor to determine if it is the right treatment for you. Source - https://helpforheallth.blogspot.com/2023/02/blincyto-385-mcg-for-acute.html

More Related